The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Non-hospitalized people with mild or moderate cases of COVID-19 are to be enrolled at sites around the world, for a test trial called ACTIV-2, which is a part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program.
